News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
June 14, 2018
Resverlogix Announces Withdrawal of Public Offering of Units
June 8, 2018
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
June 7, 2018
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
May 24, 2018
Resverlogix Announces Lifting by TSX of Review
May 10, 2018
Resverlogix Closes US$30 Million Loan
May 7, 2018
Resverlogix Advances US$30 Million Loan Closing Documentation
May 1, 2018
Resverlogix Announces Proposed Offering of Units
April 17, 2018
Resverlogix Announces TSX Review Update
April 12, 2018
Resverlogix Announces US$30 Million Loan Commitment Letter
April 11, 2018
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
March 28, 2018
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
March 19, 2018
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
February 26, 2018
Resverlogix Highlights Key Accomplishments and 2018 Targets
February 8, 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
January 11, 2018
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
January 8, 2018